Literature DB >> 1887758

Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson's disease.

R Siegemund1, J Lössner, K Günther, H J Kühn, H Bachmann.   

Abstract

The drug of choice for the initial treatment of "decoppering" in Wilson's disease, an inherited disorder of copper metabolism, is the chelating agent D-penicillamine. In the case of harmful side-effects an alternative drug is triethylenetetramine dihydrocholoride (trien or trientine). Using the 24-h-urine excretion of copper and the oral copper loading test with copper-64, a double function for trien was found: trien increases the urine copper excretion and decreases the intestinal copper absorption respectively.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1887758     DOI： 10.1111/j.1600-0404.1991.tb03964.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN： 0001-6314            Impact factor:   3.209


  9 in total

1.  Trientine selectively delivers copper to the heart and suppresses pressure overload-induced cardiac hypertrophy in rats.

Authors:  Jiaming Liu; Chen Chen; Yinjie Liu; Xiaorong Sun; Xueqin Ding; Liying Qiu; Pengfei Han; Y James Kang
Journal:  Exp Biol Med (Maywood)       Date:  2018-11-24

Review 2.  Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease.

Authors:  Garth J S Cooper
Journal:  Drugs       Date:  2011-07-09       Impact factor: 9.546

3.  A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study.

Authors:  G J S Cooper; A A Young; G D Gamble; C J Occleshaw; A M Dissanayake; B R Cowan; D H Brunton; J R Baker; A R J Phillips; C M Frampton; S D Poppitt; R N Doughty
Journal:  Diabetologia       Date:  2009-01-27       Impact factor: 10.122

4.  Suppression of 9L gliosarcoma growth by copper depletion with copper-deficient diet and D-penicillamine.

Authors:  D Yoshida; Y Ikeda; S Nakazawa
Journal:  J Neurooncol       Date:  1993-08       Impact factor: 4.130

Review 5.  Triethylene tetramine dihydrochloride (trientine) in children with Wilson disease: experience at King's College Hospital and review of the literature.

Authors:  Rachel M Taylor; Yuan Chen; Anil Dhawan
Journal:  Eur J Pediatr       Date:  2008-12-09       Impact factor: 3.183

6.  Rapid copper acquisition by developing murine mesothelioma: decreasing bioavailable copper slows tumor growth, normalizes vessels and promotes T cell infiltration.

Authors:  Andrew Crowe; Connie Jackaman; Katie M Beddoes; Belinda Ricciardo; Delia J Nelson
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

7.  Efficacy and Safety of Two Salts of Trientine in the Treatment of Wilson's Disease.

Authors:  France Woimant; Dominique Debray; Erwan Morvan; Mickael Alexandre Obadia; Aurélia Poujois
Journal:  J Clin Med       Date:  2022-07-08       Impact factor: 4.964

8.  Treatment with a copper-selective chelator causes substantive improvement in cardiac function of diabetic rats with left-ventricular impairment.

Authors:  Jun Lu; Beau Pontré; Stephen Pickup; Soon Y Choong; Mingming Li; Hong Xu; Gregory D Gamble; Anthony R J Phillips; Brett R Cowan; Alistair A Young; Garth J S Cooper
Journal:  Cardiovasc Diabetol       Date:  2013-01-31       Impact factor: 9.951

9.  Protection of the heart by treatment with a divalent-copper-selective chelator reveals a novel mechanism underlying cardiomyopathy in diabetic rats.

Authors:  Lin Zhang; Marie-Louise Ward; Anthony R J Phillips; Shaoping Zhang; John Kennedy; Bernard Barry; Mark B Cannell; Garth J S Cooper
Journal:  Cardiovasc Diabetol       Date:  2013-08-28       Impact factor: 9.951
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.